Natixis’s Acceleron Pharma XLRN Stock Holding History

Natixis’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,026	Closed	-$349K	–	1413
2021 Q3	$349K	Sell	2,026 -16	-0.8%	-$2.09K	﹤0.01%	1070
2021 Q2	$256K	Sell	2,042 -1,870	-48%	-$236K	﹤0.01%	797
2021 Q1	$531K	Sell	3,912 -254	-6%	-$32.8K	﹤0.01%	930
2020 Q4	$533K	Buy	+4,166	New	+$488K	﹤0.01%	889
2020 Q3	–	Sell	-7,522	Closed	-$717K	–	911
2020 Q2	$717K	Buy	+7,522	New	+$725K	0.01%	564
2019 Q2	–	Sell	-5,680	Closed	-$256K	–	944
2019 Q1	$256K	Sell	5,680 -3,118	-35%	-$137K	﹤0.01%	741
2018 Q4	$383K	Buy	+8,798	New	+$440K	﹤0.01%	600

Natixis's XLRN Position: Q4 2021 in Review

Natixis sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,026 shares — an estimated $349K sold.

Natixis first reported a position in XLRN in Q4 2018 and held it in 7 quarters. The position peaked at $717K in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Natixis reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Natixis sold 2,026 Acceleron Pharma shares in Q4 2021, an estimated $349K.
Natixis first reported a position in Acceleron Pharma in Q4 2018 and held it in 7 quarters.
Natixis's Acceleron Pharma position peaked at $717K in Q2 2020.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Natixis's 13F filing for Q4 2021, filed 14 Feb 2022.